Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

@article{Planas2021ReducedSO,
  title={Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.},
  author={Delphine Planas and David Veyer and Artem Baidaliuk and Isabelle Staropoli and Florence Guivel‐Benhassine and Maaran Michael Rajah and Cyril Planchais and Françoise Porrot and Nicolas Robillard and Julien Puech and Matthieu Prot and Floriane Gallais and Pierre Gantner and Aur{\'e}lie Velay and Julien Le Guen and Najibi Kassis-Chikhani and Dhiaeddine Edriss and Laurent B{\'e}lec and Aymeric S{\`e}ve and Laura Courtellemont and H{\'e}l{\`e}ne P{\'e}r{\'e} and Laurent Hocqueloux and Samira Fafi-Kremer and Thierry Prazuck and Hugo Mouquet and Timoth{\'e}e Bruel and Etienne Simon-Lori{\`e}re and F{\'e}lix A. Rey and Olivier Schwartz},
  journal={Nature},
  year={2021}
}
The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India1-5. It has since then become dominant in some indian regions and UK and further spread to many countries6. The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), harbouring diverse Spike mutations in the N-terminal domain (NTD) and the receptor binding domain (RBD) which may increase their immune evasion potential. B.1.617.2, also termed variant Delta, is believed to spread faster than other variants… Expand

Figures from this paper

Increased neutralization of SARS-CoV-2 Delta variant by nanobody (Nb22) and the structural basis
TLDR
Nb22-Fc, among the previously reported nanobodies, exhibited 8.4-fold increased neutralization potency against Delta variant with an IC50 value of 0.41 ng/ml (5.13 pM) relative to Alpha variant, and crystal structural analysis reveals that Nb22 on SARS-CoV-2 RBD effectively blocks the binding of RBD to ACE2 during virus infection. Expand
Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants
TLDR
A previously uncharacterized class of N-terminal domain-directed human neutralizing monoclonal antibodies cross-reacting with several variants of concern is described, revealing a possible target for vaccine development. Expand
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
  • P. Arora, Amy Kempf, +9 authors Markus Hoffmann
  • Medicine
  • Cellular & molecular immunology
  • 2021
TLDR
This study sought to determine whether Delta Plus and Delta-V differ from the Delta variant regarding cell entry and neutralization sensitivity by using rhabdoviral pseudotypes, which are adequate models for cell entry of SARS-CoV-2, and previously described monoclonal antibodies and sera/plasma from infected or BNT162b2/Comirnaty vaccinated individuals. Expand
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
TLDR
Some of the most promising broadly neutralizing antibodies obtained from plasma of patients that recovered from early variants of SARS-CoV-2 that may be effective against emerging new variants of the virus are reviewed. Expand
Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients
TLDR
It is highlighted that the BNT162b2 vaccine stimulates a humoral response able to neutralize all tested SARS-CoV-2 variants, thus suggesting a prominent role in mitigating the impact of the Sars-Cov-2 pandemic in real-world conditions. Expand
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
TLDR
It is shown that SARS-CoV-2 variants can elicit polyclonal antibodies with different immunodominance hierarchies and that neutralization by these antibodies is notably less affected by mutations at residue 484. Expand
Neutralization of recombinant RBD-subunit vaccine ZF2001-elicited antisera to SARS-CoV-2 variants including Delta
TLDR
This work evaluated the neutralization of ZF2001-elicited antisera to SARS-CoV-2 variants including all four variants of concern and other three variants of interest by pseudovirus-based assay and found antisers preserved majority of the neutralizing activity against these variants. Expand
SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19
  • Maochen Li, Fuxing Lou, Huahao Fan
  • Medicine
  • Signal Transduction and Targeted Therapy
  • 2021
TLDR
This work evaluated the effects of monoclonal antibodies, convalescent serum, and vaccines on Delta variant, which leads to concerns about the effectiveness of current vaccines to the upcoming SARS-CoV-2 variants, and found that one dose of BNT162b2 vaccination after natural infection could provide effective protection against variant Alpha, Beta, and Delta. Expand
Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan, China
TLDR
It is suggested that SARS-CoV-2 can elicit long-lasting immunity but escaped by the emerging variants, with individuals showing remarkably broad neutralization potency. Expand
Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases
The SARS-CoV-2 variant of concern (VOC) B.1.617.2 (Delta) has rapidly spread to constitute more than 95% of the circulating lineages in France by August, 2021, and the situation is similar worldwideExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough
TLDR
In an analysis of over 130 SARS-CoV-2 infected healthcare workers across three centres in India during a period of mixed lineage circulation, substantially reduced ChAdOx-1 vaccine efficacy against B.617.1.2 Delta variant warrants continued infection control measures in the post-vaccination era. Expand
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
TLDR
This study reveals that antibody evasion of B.1.1,1.617 may contribute to the rapid spread of this variant of SARS-CoV-2, and indicates that it is resistant against Bamlanivimab, an antibody used for COVID-19 treatment. Expand
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
TLDR
The recent emergence of new SARS-CoV-2 variants B.2.1.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines. Expand
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
TLDR
The susceptibility of these newly emerged variants to BNT162b2 vaccine-elicited neutralization supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic across geographies. Expand
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
TLDR
Therefore, faster-spreading SARS-CoV-2 variants acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which was most frequently detected in individuals with low antibody levels. Expand
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
TLDR
A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres, suggesting both of these regions at the top of the viral spike are immunogenic. Expand
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
TLDR
Eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD are solved and rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use are provided. Expand
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
TLDR
41 human monoclonal Abs derived from memory B cells are described, which recognize the SARS-CoV-2 S N-terminal domain (NTD) and it is shown that a subset of them neutralize Sars-Cov-2 ultrapotently. Expand
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
TLDR
After 2 doses of either vaccine there were only modest differences in vaccine effectiveness with the B.1. Expand
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
TLDR
Complete maps of SARS-CoV-2 mutations that escape the Regeneron monoclonal antibody cocktail help explain viral evolution in a treated patient and enable interpretation of the consequences of mutations observed during viral surveillance. Expand
...
1
2
3
...